What it is:An age-related, non-cancerous overgrowth of the prostate that squeezes down on the urethra as it passes through the gland. Almost every man gets some degree of it if he lives long enough (about 8% by his 40s, roughly 80% by his 80s and 90s).
The core problem:Two separate mechanisms narrow the urethra, and they don't respond to the same drugs. A staticcomponent (the gland is physically bigger, driven by dihydrotestosterone) and a dynamiccomponent (the smooth muscle around the urethra and bladder neck is clamped down by α1-adrenergic tone). You have to know which one you're treating.
What you do about it:Mild disease gets watched. Moderate disease gets a drug matched to whichever mechanism dominates, usually an α1-blocker first because it works in days. Severe disease or complications go to surgery.
Think of BPH as "one pipe, two ways to pinch it."α1-blockers relax the pinch (dynamic, fast, doesn't shrink anything). 5α-reductase inhibitors (5-ARIs) shrink the pipe wall itself (static, slow, only works if the gland is actually big). Picking the wrong tool for the wrong mechanism is the single most common reasoning error on this topic.
Three related terms get used almost interchangeably, but they mean different things and it's worth keeping them straight.
| Term | What it actually means |
|---|---|
| BPH(benign prostatic hyperplasia) | The histologic diagnosis, cellular overgrowth of the gland |
| BPE(benign prostatic enlargement) | The gland is measurably bigger on exam or imaging |
| BPO(benign prostatic obstruction) | Urodynamically confirmed outflow obstruction, i.e. it's actually blocking flow |
Severity is graded with the AUA Symptom Score / International Prostate Symptom Score (IPSS), seven questions on obstructive and irritative symptoms (0–5 each, max 35) plus a separate quality-of-life question. A 3-point changeis considered clinically meaningful, that's the number to watch on follow-up.
| Severity | AUA/IPSS Score | Typical picture |
|---|---|---|
| Mild | ≤7 | Often asymptomatic; peak flow <10 mL/sec; PVR 25–50 mL |
| Moderate | 8–19 | Above, plus obstructive and irritative voiding symptoms (early detrusor instability) |
| Severe | ≥20 | Above, plus one or more BPH complications |
Severity, not gland size alone, sets the treatment tier: mild → watchful waiting, moderate → pharmacotherapy, severe or complicated → surgery(or pharm as a bridge). Gland size and PSA then decide which drugwithin the pharm tier.
The prostate has three tissue types: glandular/epithelial, stromal (smooth muscle), and capsule. The exact trigger for BPH isn't fully worked out, but it clearly runs through androgen signalingand it clearly involves two separable factors, and every drug class on this chapter maps to one of them.
Testosterone is converted to dihydrotestosterone (DHT)by the enzyme 5α-reductase. DHT is the more potent androgen at the prostate and drives overgrowth of both the stromal and epithelial cells. There are two isoenzymes: type 2is the dominant one in the prostate, type 1is more active in skin and liver. That distinction matters later, it's exactly what separates finasteride from dutasteride.
The stroma and capsule are loaded with α1-adrenergic receptors. Anything that raises adrenergic tone, whether it's sympathetic activation, decongestants, or just baseline autonomic drive, constricts that smooth muscle and narrows the channel independent of how big the gland actually is. This is why a man can have severe symptoms with a normal-sized prostate, or a huge prostate with mild symptoms.
Static and dynamic factors are why there are two completely different drug strategies. α1-blockersattack the dynamic factor, they relax the smooth muscle and work within days, but they never shrink anything. 5-ARIsattack the static factor, they block DHT formation and shrink the gland over months, but they do nothing for the smooth muscle tone. Neither one is "better," they're solving different halves of the same pipe.
Testosteroneand other androgens (feeds the static factor directly). α-adrenergic agonistslike decongestants (worsens the dynamic factor). Anything with meaningful anticholinergic activity, antihistamines, phenothiazines, TCAs, antispasmodics, antiparkinsonian agents, since blocking bladder contraction on top of an obstructed outlet promotes retention. Course material also flags SNRIsand diuretics/caffeine(the latter two aggravate irritative symptoms rather than true obstruction). This list is a favorite "which OTC product should this patient avoid" exam trap.
Symptoms are grouped as obstructiveor irritative, and together they're called lower urinary tract symptoms (LUTS). Remember that LUTS is not specific to BPH, neurogenic bladder and UTI cause the same complaints, so LUTS alone doesn't confirm the diagnosis.
| Category | Mechanism | Symptoms |
|---|---|---|
| Obstructive | Reduced bladder emptying from the physical/functional blockage | Hesitancy, weak or interrupted stream, straining to start, dribbling, sensation of incomplete emptying |
| Irritative | Long-standing obstruction at the bladder neck irritates the detrusor | Frequency, urgency, nocturia |
Urinary retention, chronic kidney disease, gross hematuria, urinary incontinence, recurrent UTI, bladder diverticula, and bladder stones. Any of these bump a patient straight into the "severe / consider surgery" bucket regardless of the numeric AUA score.
Diagnosis is built from history, exam, objective flow measures, and labs, there's no single confirmatory test.
A PSA below 1.5 ng/mLsuggests the gland is probably too small for a 5-ARI to add much benefit. DiPiro frames the combination-therapy trigger as a gland >40 g and PSA ≥1.4 ng/mLwith moderate-to-severe symptoms. These are close but not identical cutoffs across sources, the concept to hold onto is bigger gland + higher PSA = more static component = more reason to add a 5-ARI, not the exact decimal.
5-ARIs cut PSA roughly in half over about 6 months in a normal responder. Check PSA at baseline and again at 6 months; if it hasn't dropped by 50% in an adherent patient, work them up for prostate cancerrather than assuming the drug just isn't working. Course material used this exact setup as a NAPLEX-style distractor (elevated PSA on dutasteride, don't just shrug it off as expected).
Goals:control symptoms, prevent progression and complications, and delay (or avoid) surgery.
Reserved for mild disease. Reassess every 6–12 months. Counsel on behavior modification: restrict fluids before bedtime, cut back caffeine and alcohol, empty the bladder frequently and completely, and avoid the drug list above that worsens symptoms.
Appropriate for moderatesymptoms, and used as a bridge in severedisease while awaiting or in lieu of surgery. The decision tree runs on three questions: how bad are symptoms, how big is the gland, and does the patient also have erectile dysfunction.
Combining classes can reduce bothersome symptoms further, but it also stacks adverse effects, drug interactions, cost, and pill burden, and it only produces a modestgain in objective measures. It's not a free upgrade, reserve it for patients who actually meet the size/PSA/symptom criteria above.
Transurethral resection of the prostate (TURP)remains the gold standard, done transurethrally or suprapubically. Surgery is always indicatedfor BPH complications: acute urinary retention unresponsive to drugs, chronic retention with declining renal function or overflow incontinence, urolithiasis, recurrent UTI, or recurrent hematuria. It's also appropriate for patients who fail, can't tolerate, or won't adhere to drug therapy, or who simply prefer it. Minimally invasive (TUNA, TUMT) and newer laser-based options (HoLEP, HoLAP, PVP, TUVP) exist alongside TURP and open/robotic prostatectomy.
Retrograde ejaculation complicates up to 75%of TURP procedures, warn patients this is expected, not a complication to panic over. Bleeding, urinary incontinence, and erectile dysfunction occur in roughly 2–15%.
Organized by the mechanism each class hits. Titration matters most for the non-selective α1-blockers, everything else is largely fixed-dose.
| Drug | Initial | Usual / Target | Notes |
|---|---|---|---|
| Non-selective α1-blockers (also hit vascular α1B/1D → BP effects, titrate) | |||
| Terazosin (Hytrin) | 1 mg at bedtime | 10 mg daily (up to 20 mg) | Double dose q2wk-ish per titration schedule; caution with other BP-lowering drugs |
| Doxazosin IR (Cardura) | 1 mg daily | 8 mg daily | Titrate over ~6 weeks (1→2→4→8 mg) |
| Doxazosin XL (Cardura XL) | 4 mg daily | 4–8 mg daily | Switching from IR: always restart at 4 mg XL regardless of IR maintenance dose |
| Prazosin (Minipress) | 0.5 mg BID | 1–5 mg BID | Not recommended by current guidelines (multiple daily doses, more CV effects) |
| Alfuzosin (Uroxatral) | 10 mg daily | 10 mg daily, no titration | ER, do not crush/chew; take after a meal; "uroselective," fewer CV effects than other 2nd-gen agents; avoid if CrCl <30 |
| Selective α1A-blockers (prostate-specific, minimal CV effect) | |||
| Tamsulosin (Flomax) | 0.4 mg daily | 0.4–0.8 mg daily | ~30 min after the same meal daily; no titration needed for renal/hepatic impairment |
| Silodosin (Rapaflo) | 8 mg daily | 8 mg daily, no titration | 4 mg daily if CrCl 30–50; contraindicated CrCl <30 or with potent CYP3A4 inhibitors |
| 5α-Reductase inhibitors (shrink the gland, months to work) | |||
| Finasteride (Proscar) | 5 mg daily | 5 mg daily, no titration | Type 2 selective; 1 mg dose is a different drug indication(Propecia, alopecia) |
| Dutasteride (Avodart) | 0.5 mg daily | 0.5 mg daily, no titration | Inhibits type 1 andtype 2, broader blockade than finasteride |
| Dutasteride/tamsulosin (Jalyn) | 1 tablet daily | 1 tablet daily | Fixed combo for gland >40 g + elevated PSA candidates |
| PDE5 inhibitor (only when BPH + ED overlap) | |||
| Tadalafil (Cialis) | 5 mg daily | 5 mg daily, no titration | 2.5 mg daily if CrCl 30–50; avoid if CrCl <30 or severe hepatic impairment |
| β3-agonists (detrusor relaxants, add-on for irritative symptoms) | |||
| Mirabegron (Myrbetriq) | 25 mg daily | up to 50 mg daily | Moderate CYP2D6 inhibitor; can raise BP/HR; max 25 mg if CrCl 15–29 or moderate hepatic impairment |
| Vibegron (Gemtesa) | 75 mg daily | 75 mg daily, no titration | Less effect on BP/HR than mirabegron; avoid if CrCl <15 |
| Anticholinergics (add-on for persistent irritative symptoms; check PVR first) | |||
| Oxybutynin IR / XL (Ditropan) | 5 mg 2–3x/day (IR) or 5 mg daily (XL) | Up to 30 mg/day (XL) | Titrate 5 mg increments weekly; also available transdermal (Oxytrol) and gel (Gelnique) |
| Tolterodine IR / ER (Detrol / Detrol LA) | 1–2 mg BID (IR) or 2–4 mg daily (LA) | 2 mg BID (IR) / 4 mg daily (LA) | Reduce dose with significant renal or severe hepatic impairment |
| Darifenacin (Enablex) | 7.5 mg daily | 7.5–15 mg daily | Selective M3 blockade; cap at 7.5 mg with potent CYP3A4 inhibitors |
| Solifenacin (Vesicare) | 5 mg daily | 5–10 mg daily | Selective M3 blockade; cap at 5 mg with CrCl <30, moderate hepatic impairment, or potent CYP3A4 inhibitor |
| Trospium IR / XR (Sanctura) | 20 mg BID (IR) or 60 mg daily (XR) | 20 mg BID / 60 mg daily | Minimal blood-brain barrier penetration, preferred in older adults; IR only, lower dose if age >75 |
| Fesoterodine (Toviaz) | 4 mg daily | 4–8 mg daily | Cap at 4 mg with CrCl <30 or potent CYP3A4 inhibitor |
All α1-blockers relax smooth muscle in the prostate and bladder neck, boosting urinary flow rate by roughly 2–3 mL/sec in 60–70%of patients and cutting PVR. They do notshrink the gland or lower PSA, that's the 5-ARIs' job. Second- and third-generation agents are considered equally effective for symptom control, they mainly differ in side-effect burden.
Second-generation, non-selective(prazosin, terazosin, doxazosin, alfuzosin): these also hit vascular α1B/1D receptors, so they cause first-dose syncope, orthostatic hypotension, and dizziness. Terazosin and doxazosin IR need dose titration to blunt this. Prazosin isn't recommended anymore, it needs multiple daily doses and carries the worst CV side-effect profile. Alfuzosin is the outlier in this group, it's functionally uroselective and causes fewer CV effects than the others despite being "non-selective" by receptor binding.
Third-generation, selective(tamsulosin, silodosin): selective for the α1Asubtype, which makes up about 70% of prostatic receptors, so they largely spare peripheral vasculature. Minimal titration, onset within about a week, but not very useful as antihypertensives, and dizziness/fainting can still occur.
α1-blockers (tamsulosin especially) relax the iris dilator muscle, which can cause a floppy iris during cataract surgery. Tell the ophthalmologist the patient is on an α1-blocker before surgery, even stopping the drug in advance doesn't reliably prevent it since the effect can persist. This is a classic "counsel before a planned procedure" exam and practice point.
Interactions:CYP3A4 inhibitors (cimetidine, diltiazem) slow α1-blocker metabolism and increase levels/effect; CYP3A4 inducers (carbamazepine, phenytoin) do the opposite.
5-ARIs block the conversion of testosterone to DHT, hitting the staticfactor directly. Finasterideselectively inhibits type 25α-reductase. Dutasterideinhibits both type 1 and type 2, a broader blockade. Compared to α1-blockers, 5-ARIs take 6–12 monthsto maximally shrink the gland, are less likely to produce a fast objective symptom improvement, and cause more sexual dysfunction, so they're generally considered second-line in men who are still sexually active.
What they're actually good for: slowing disease progression and lowering the risk of complicationslike acute urinary retention, which α1-blockers don't do. They're preferred over α1-blockers in patients with uncontrolled arrhythmias, poorly controlled angina, patients already on multiple antihypertensives, or anyone who can't tolerate the hypotensive effects of an α1-blocker.
Finasteride 1 mg (Propecia)is for androgenic alopecia. Finasteride 5 mg (Proscar)is for BPH. Same drug, five-fold dose difference, different brand, different indication. The 1 mg dose causes noticeably less sexual dysfunction than the 5 mg dose used for BPH, that's a direct dose-response, not a different side-effect profile.
5-ARIs are contraindicated in pregnancy. Women who are pregnant or trying to become pregnant should not handle crushed/broken tabletsand should avoid contact with semenfrom a partner taking one, since it can affect a male fetus's genital development.
Side effects:sexual dysfunction (ED, decreased libido, ejaculatory dysfunction), gynecomastia/breast tenderness. Monitoring:baseline PSA, recheck at 6 months, expect roughly a 50% drop in an adherent responder; if it doesn't drop, work up for prostate cancer instead of assuming nonadherence or drug failure.
Tadalafilraises cGMP, relaxing smooth muscle in the prostate, urethra, pelvic vessels, and bladder neck. At the 5 mg BPH dose it improves voiding symptoms but does not increase flow rate or reduce PVR, unlike α1-blockers, which is a useful distinction to hold onto. Combined with an α1-blocker it does improve LUTS, flow rate, and PVR more than either alone, but combined with a 5-ARI specifically, the added benefit over finasteride alone is minimal, not a combination worth reaching for by itself.
β3-agonists (mirabegron, vibegron)relax the detrusor without anticholinergic effects, easing irritative symptoms and increasing bladder capacity. Guidelines currently support them only in combination with an α1-blocker, not as monotherapy for BPH-related LUTS. Mirabegron is a moderate CYP2D6 inhibitor and can raise BP/HR; vibegron has less cardiovascular effect but more nausea.
Anticholinergics (oxybutynin, tolterodine, darifenacin, solifenacin, trospium, fesoterodine)relieve irritative symptoms by relaxing the detrusor, added on when those symptoms persist despite an optimized α1-blocker. Check PVR before starting, DiPiro's cutoff is under 150 mL, course material flags avoiding them above 250–300 mL, either way the point is the same: don't add an anticholinergic on top of a bladder that's already not emptying, you can precipitate retention. Darifenacin and solifenacin are selective for M3 receptors (less dry mouth/CNS effect than non-selective agents); trospium and fesoterodine cross the blood-brain barrier poorly, making them the preferred choice in older adults at risk for sedation or confusion. Extended-release formulations are generally better tolerated than immediate-release across this whole class.
| Parameter | When | Watching for |
|---|---|---|
| AUA/IPSS score | Baseline, then each follow-up | A ≥3-point change is clinically meaningful, either direction |
| PSA | Baseline; at 6 months if starting a 5-ARI | Expect ~50% drop on a 5-ARI in an adherent responder; failure to drop → evaluate for prostate cancer |
| Blood pressure / orthostatics | Baseline and with each α1-blocker titration | Symptomatic hypotension, first-dose syncope, especially with non-selective agents |
| PVR urine volume | Before starting an anticholinergic; periodically after | Urinary retention risk; hold/avoid if PVR is elevated per the cutoff you're using |
| Renal function (BUN, SCr) | Periodically, more often with retention or CKD | Obstructive nephropathy from chronic retention |
| Symptom response overall | 6–12 weeks after starting therapy | Time point DiPiro specifies for assessing efficacy of a new regimen |
| Annual DRE + PSA | Every year if life expectancy ≥10 years | Prostate cancer surveillance, separate from BPH management itself |